NCT04100772View on ClinicalTrials.gov

Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above

PHASE1CompletedINTERVENTIONAL
Enrollment

237

Participants

Timeline

Start Date

May 18, 2020

Primary Completion Date

June 23, 2021

Study Completion Date

August 23, 2022

Conditions
Pneumococcal InfectionsStreptococcal InfectionsBacterial Infections
Interventions
BIOLOGICAL

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）

0.5mL,Intramuscular other name:PCV13i

BIOLOGICAL

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

0.5mL,Intramuscular other name:Prevnar

Trial Locations (1)

450016

Neihuang Center for Disease Control and Prevention, Anyang

Sponsors
All Listed Sponsors
collaborator

Henan Center for Disease Control and Prevention

OTHER_GOV

lead

CanSino Biologics Inc.

INDUSTRY

NCT04100772 - Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above | Biotech Hunter | Biotech Hunter